华东医药
(000963)
| 流通市值：720.05亿 | | | 总市值：720.93亿 |
| 流通股本：17.52亿 | | | 总股本：17.54亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 10,735,787,899.82 | 41,905,707,385.91 | 31,477,654,750.5 | 20,965,065,605.67 |
| 营业收入 | 10,735,787,899.82 | 41,905,707,385.91 | 31,477,654,750.5 | 20,965,065,605.67 |
| 二、营业总成本 | 9,620,007,130.43 | 37,493,020,210.87 | 28,288,811,654.13 | 18,876,799,219.53 |
| 营业成本 | 7,206,598,136.26 | 27,988,547,185.82 | 21,231,803,408.72 | 14,109,803,647.16 |
| 税金及附加 | 57,265,200.91 | 250,638,795.43 | 163,791,954.73 | 111,008,570.22 |
| 销售费用 | 1,470,753,504.47 | 6,408,522,136.28 | 4,727,512,478.83 | 3,274,822,873.39 |
| 管理费用 | 355,395,350.66 | 1,397,388,188.96 | 1,179,023,165.24 | 714,633,116.91 |
| 研发费用 | 515,376,918.47 | 1,425,659,218.47 | 948,662,894.53 | 643,106,566.65 |
| 财务费用 | 14,618,019.66 | 22,264,685.91 | 38,017,752.08 | 23,424,445.2 |
| 其中:利息费用 | 25,924,507.3 | 101,203,829.32 | 86,594,008.13 | 55,550,660.47 |
| 其中:利息收入 | 27,812,843.06 | 103,997,474.21 | 80,012,995.89 | 53,142,421.17 |
| 加:投资收益 | -42,624,149.61 | -129,190,728.94 | -86,710,253.53 | -47,845,863.81 |
| 资产处置收益 | -14,540,990.32 | -5,463,399.18 | 2,177,150.46 | 4,927,280.24 |
| 资产减值损失(新) | - | -41,006,057.96 | - | - |
| 信用减值损失(新) | - | -112,179,415.6 | -57,939,915.17 | -57,939,915.37 |
| 其他收益 | 73,641,636.88 | 199,889,752.54 | 168,982,096.89 | 93,707,046.82 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,132,257,266.34 | 4,324,737,325.9 | 3,215,352,175.02 | 2,081,114,934.02 |
| 加:营业外收入 | 769,095.39 | 88,009,280.04 | 7,442,671.2 | 5,221,955.01 |
| 减:营业外支出 | 28,075,417.91 | 111,232,726.47 | 88,911,294.16 | 37,784,277.75 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,104,950,943.82 | 4,301,513,879.47 | 3,133,883,552.06 | 2,048,552,611.28 |
| 减:所得税费用 | 190,966,760.4 | 807,328,247.71 | 571,279,294.45 | 360,337,560.24 |
| 六、净利润 | 913,984,183.42 | 3,494,185,631.76 | 2,562,604,257.61 | 1,688,215,051.04 |
| 持续经营净利润 | 913,984,183.42 | 3,494,185,631.76 | 2,562,604,257.61 | 1,688,215,051.04 |
| 归属于母公司股东的净利润 | 914,708,484.7 | 3,512,104,678.06 | 2,562,326,688.45 | 1,696,020,589.2 |
| 少数股东损益 | -724,301.28 | -17,919,046.3 | 277,569.16 | -7,805,538.16 |
| (一)基本每股收益 | 0.52 | 2 | 1.46 | 0.97 |
| (二)稀释每股收益 | 0.52 | 2 | 1.46 | 0.97 |
| 八、其他综合收益 | 82,044,972.47 | -10,256,659.99 | 17,675,896.3 | -6,285,502.28 |
| 归属于母公司股东的其他综合收益 | 82,044,972.47 | -10,256,659.99 | 17,675,896.3 | -6,285,502.28 |
| 九、综合收益总额 | 996,029,155.89 | 3,483,928,971.77 | 2,580,280,153.91 | 1,681,929,548.76 |
| 归属于母公司股东的综合收益总额 | 996,753,457.17 | 3,501,848,018.07 | 2,580,002,584.75 | 1,689,735,086.92 |
| 归属于少数股东的综合收益总额 | -724,301.28 | -17,919,046.3 | 277,569.16 | -7,805,538.16 |
| 公告日期 | 2025-04-25 | 2025-04-18 | 2024-10-25 | 2024-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |